Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the sale, the chief executive officer owned 1,172,987 shares in the company, valued at approximately $74,308,726.45. This represents a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 14th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $81.11, for a total transaction of $1,622,200.00.
• On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.38, for a total transaction of $1,507,600.00.
• On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.01, for a total value of $3,000,400.00.

Apogee Therapeutics Price Performance

NASDAQ APGE traded down $1.53 during trading hours on Friday, reaching $67.78. The company’s stock had a trading volume of 1,167,673 shares, compared to its average volume of 1,038,820. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of -15.47 and a beta of 1.42. The company’s 50-day moving average is $74.39 and its two-hundred day moving average is $57.22. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APGE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after acquiring an additional 694 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after purchasing an additional 130,164 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Apogee Therapeutics in the second quarter valued at approximately $218,000. AlphaQuest LLC increased its holdings in shares of Apogee Therapeutics by 344.6% in the second quarter. AlphaQuest LLC now owns 5,073 shares of the company’s stock valued at $220,000 after purchasing an additional 3,932 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after purchasing an additional 383 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on APGE shares. Stifel Nicolaus set a $133.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Mizuho assumed coverage on shares of Apogee Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $105.00 target price for the company. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Sunday, January 25th. Deutsche Bank Aktiengesellschaft initiated coverage on Apogee Therapeutics in a report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price objective on the stock. Finally, Craig Hallum reiterated a “buy” rating and set a $116.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.58.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.